Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery

• Status: Completed
• Trial end date: 2017-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate superior efficacy of DE-108 ophthalmic solution to that of Levofloxacin 0.5% ophthalmic solution as well as safety of the former used for perioperative bacteria eradication in patients who are scheduled for cataract surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Pharmaceutical Co., Ltd.
• Treatments: Levofloxacin; Ofloxacin; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Those who are scheduled for cataract surgery

Exclusion Criteria:

• Those who with suspected ocular infections based on clinical findings in the study eye.

• Those who have any eye disease other than cataract which requires treatment in the target eye.

• Those who have a history of allergy to the drugs to be used during the clinical study (such as fluoroquinolones, topical anesthetics and povidon iodine)

• Those who need to wear contact lenses during the study period